Identification

Name
Citric Acid
Accession Number
DB04272  (EXPT00922)
Type
Small Molecule
Groups
Approved, Nutraceutical, Vet Approved
Description

A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.

Structure
Thumb
Synonyms
  • 2-Hydroxytricarballylic acid
  • 3-Carboxy-3-hydroxypentane-1,5-dioic acid
  • Citric Acid, Anhydrous
  • Citronensäure
External IDs
FEMA NO. 2306 / NSC-112226 / NSC-30279 / NSC-626579
Product Ingredients
IngredientUNIICASInChI Key
Citric acid monohydrate2968PHW8QP5949-29-1YASYEJJMZJALEJ-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hand WashingLiquid.3 g/100gTopicalNINGBO JIANGBEI OCEAN STAR TRADING CO.,LTD2016-09-26Not applicableUs
Whitening Lemon PeelLiquid.007 g/mLTopicalAmi Cosmetic Co.,Ltd.2013-08-31Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ACD Solution ModifiedSolution8 mg/mLIntravenousAnazao Health Corporation2012-05-23Not applicableUs
bdr Re-action natural low base skin refiner exfoliation essenceLiquid1.5 g/30mLTopicalHanaim International Llc2016-11-14Not applicableUs
Stop HairSpray7 mg/mLTopicalMila Beauty Pty Ltd2012-07-01Not applicableUs
Stop HairSpray.7 mg/100mLTopicalStop Hair Pty Ltd2012-09-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
A-C-D SolutionCitric Acid (80 mg) + Glucose (132 mg) + Sodium Citrate (250 mg)LiquidIntravenousDraximage A Division Of Draxis Specialty Pharmaceuticals Inc1959-12-312003-07-08Canada
Acd ACitric acid monohydrate (.8 g/100mL) + Glucose (2.45 g/100mL) + Sodium Citrate (2.2 g/100mL)Injection, solutionIntravenousTerumo Bct2002-02-25Not applicableUs
ACD Blood-Pack Units (PL 146 Plastic)Citric Acid (493 mg/67.5mL) + Dextrose monohydrate (1.65 g/67.5mL) + Trisodium citrate dihydrate (1.48 g/67.5mL)SolutionIntravenousFenwal, Inc.2007-03-01Not applicableUs
Acd-ACitric Acid (730 mg/100mL) + Dextrose monohydrate (2.45 g/100mL) + Sodium Citrate (2.2 g/100mL)SolutionIntravenousFenwal, Inc.2012-10-24Not applicableUs
Acd-ACitric acid monohydrate (.73 g/100mL) + Glucose (2.45 g/100mL) + Sodium Citrate (2.2 g/100mL)SolutionIntravenousHaemonetics Corporation1987-11-06Not applicableUs
Acd-ACitric Acid (7.3 g/1000mL) + Dextrose monohydrate (24.5 g/1000mL) + Sodium Citrate (22 g/1000mL)SolutionIntravenousFenwal, Inc.2007-03-01Not applicableUs
Additive Solution Formula 3 As-3Citric acid monohydrate (0.042 g) + Adenine (0.030 g) + Glucose (1.10 g) + Sodium Chloride (0.410 g) + Trisodium citrate dihydrate (0.588 g) + Sodium phosphate, monobasic, monohydrate (0.276 g)SolutionUnknownTerumo Bct, Inc.2013-05-31Not applicableCanada
Alka SeltzerCitric Acid (1000 mg/1) + Acetylsalicylic acid (325 mg/1) + Sodium bicarbonate (1916 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka SeltzerCitric Acid (1000 mg/1) + Acetylsalicylic acid (325 mg/1) + Sodium bicarbonate (1916 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka Seltzer EvtCitric Acid (1 g) + Acetylsalicylic acid (325 mg) + Sodium bicarbonate (1.916 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1977-12-311996-09-09Canada
Categories
UNII
XF417D3PSL
CAS number
77-92-9
Weight
Average: 192.1235
Monoisotopic: 192.02700261
Chemical Formula
C6H8O7
InChI Key
KRKNYBCHXYNGOX-UHFFFAOYSA-N
InChI
InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
IUPAC Name
2-hydroxypropane-1,2,3-tricarboxylic acid
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCell division protein FtsZNot AvailableMycobacterium tuberculosis
UAngiogeninNot AvailableHuman
UBeta-lactamase 2Not AvailableBacillus cereus
UUridine-cytidine kinase 2Not AvailableHuman
UTumor necrosis factor ligand superfamily member 13BNot AvailableHuman
UBetaine--homocysteine S-methyltransferase 1Not AvailableHuman
UTryptophan--tRNA ligaseNot AvailableGeobacillus stearothermophilus
UAldose reductaseNot AvailableHuman
UCitrate synthase, mitochondrialNot AvailableHuman
UHeparan sulfate glucosamine 3-O-sulfotransferase 3A1Not AvailableHuman
UcGMP-specific 3',5'-cyclic phosphodiesteraseNot AvailableHuman
UProto-oncogene tyrosine-protein kinase SrcNot AvailableHuman
URibonuclease pancreaticNot AvailableHuman
UIsocitrate dehydrogenase [NADP]Not AvailableBacillus subtilis (strain 168)
UGlycine N-methyltransferaseNot AvailableHuman
UEosinophil cationic proteinNot AvailableHuman
UBeta-lactamaseNot AvailableBacillus licheniformis
UMolybdenum cofactor guanylyltransferaseNot AvailableEscherichia coli (strain K12)
UFumarate hydratase class IINot AvailableEscherichia coli (strain K12)
U6-phosphogluconolactonaseNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UOxygen-insensitive NAD(P)H nitroreductaseNot AvailableEscherichia coli (strain K12)
UGag-Pro-Pol polyproteinNot AvailableRSV-SRA
UL-amino-acid oxidaseNot AvailableHuman
UMacrophage migration inhibitory factorNot AvailableHuman
UCarboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1Not AvailableHuman
U1-deoxy-D-xylulose 5-phosphate reductoisomeraseNot AvailableEscherichia coli (strain K12)
UTryptophan synthase alpha chainNot AvailableThermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)
USialidaseNot AvailableMicromonospora viridifaciens
UKHG/KDPG aldolaseNot AvailableEscherichia coli (strain K12)
UCytochrome c peroxidaseNot AvailableMarinobacter hydrocarbonoclasticus
UHepatocyte growth factor-regulated tyrosine kinase substrateNot AvailableHuman
UInvasinNot AvailableYersinia pseudotuberculosis serotype I (strain IP32953)
UIntron-associated endonuclease 1Not AvailableEnterobacteria phage T4
UShort tail fiber proteinNot AvailableEnterobacteria phage T4
UMalate dehydrogenase, mitochondrialNot AvailableHuman
UN5-carboxyaminoimidazole ribonucleotide mutaseNot AvailableAcetobacter aceti
U50S ribosomal protein L4Not AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UCarboxypeptidase BNot AvailableHuman
UHexon proteinNot AvailableHAdV-2
URiboflavin biosynthesis protein RibFNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UBeta-fructosidaseNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UPutative stringent starvation protein ANot AvailableYersinia pestis
UCitrate synthaseNot AvailableThermus thermophilus
URNA 3'-terminal phosphate cyclaseNot AvailableEscherichia coli (strain K12)
UU6 snRNA-associated Sm-like protein LSm6Not AvailableHuman
UPleckstrin homology domain-containing family A member 1Not AvailableHuman
UFe(3+)-binding periplasmic proteinNot AvailableSerratia marcescens
USignal recognition particle receptor FtsYNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UNicotinate-nucleotide adenylyltransferaseNot AvailableShigella flexneri
UN utilization substance protein B homologNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UComplement component C8 gamma chainNot AvailableHuman
URibonucleoside-diphosphate reductase subunit betaNot AvailableMycobacterium leprae (strain TN)
UGlutamine synthetase 1Not AvailableMycobacterium tuberculosis
UCitrate synthaseNot AvailableAntarctic bacterium DS2-3R
UProstaglandin F synthaseNot AvailableTrypanosoma brucei brucei
UAdenine phosphoribosyltransferaseNot AvailableHuman
UGlucose-1-phosphate thymidylyltransferaseNot AvailablePseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
UGlyoxalase family proteinNot AvailableBacillus cereus (strain ATCC 14579 / DSM 31)
ULaccase domain protein YfiHNot AvailableEscherichia coli (strain K12)
URibose-5-phosphate isomerase ANot AvailableHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UGMP synthase [glutamine-hydrolyzing]Not AvailableEscherichia coli (strain K12)
UInosine triphosphate pyrophosphataseNot AvailableHuman
ULysozymeNot AvailableEnterobacteria phage P1
UGlycerol uptake operon antiterminator regulatory proteinNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
U3-carboxy-cis,cis-muconate cycloisomeraseNot AvailablePseudomonas putida
UPyruvate decarboxylaseNot AvailableZymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

ORAL (LD50): Acute: 5040 mg/kg [Mouse]. 3000 mg/kg [Rat].

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
The oncogenic action of FumarateDisease
2-ketoglutarate dehydrogenase complex deficiencyDisease
Warburg EffectMetabolic
Citric Acid CycleMetabolic
Transfer of Acetyl Groups into MitochondriaMetabolic
Glutaminolysis and CancerDisease
Congenital lactic acidosisDisease
Fumarase deficiencyDisease
Mitochondrial complex II deficiencyDisease
Pyruvate dehydrogenase deficiency (E2)Disease
Pyruvate dehydrogenase deficiency (E3)Disease
The oncogenic action of 2-hydroxyglutarateDisease
The oncogenic action of SuccinateDisease
The oncogenic action of L-2-hydroxyglutarate in HydroxygluaricaciduriaDisease
The oncogenic action of D-2-hydroxyglutarate in Hydroxygluaricaciduria Disease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Citric Acid.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Citric Acid.Approved, Investigational
AcemetacinAcemetacin may increase the anticoagulant activities of Citric Acid.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Citric Acid.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Citric Acid.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Citric Acid.Approved, Withdrawn
AllylestrenolThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Citric Acid.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Citric Acid.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Citric Acid.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Citric Acid.Approved
AltrenogestThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Citric Acid.Investigational
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Citric Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Citric Acid.Approved
AncrodCitric Acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Citric Acid.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Citric Acid.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Citric Acid.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Citric Acid.Approved
Antithrombin III humanCitric Acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Citric Acid.Approved
ApocyninApocynin may increase the anticoagulant activities of Citric Acid.Investigational
ApremilastApremilast may increase the anticoagulant activities of Citric Acid.Approved, Investigational
ArdeparinArdeparin may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Citric Acid.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Citric Acid.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Citric Acid.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Citric Acid.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Citric Acid.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Citric Acid.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Citric Acid.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Citric Acid.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Citric Acid.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Citric Acid.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Citric Acid.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Citric Acid.Approved
BeraprostBeraprost may increase the anticoagulant activities of Citric Acid.Investigational
BevoniumBevonium may increase the anticoagulant activities of Citric Acid.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Citric Acid.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Citric Acid.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Citric Acid.Approved
BucillamineBucillamine may increase the anticoagulant activities of Citric Acid.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Citric Acid.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Citric Acid.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Citric Acid.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Citric Acid.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Citric Acid.Approved
CarprofenCarprofen may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Citric Acid.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Citric Acid.Approved, Investigational
CertoparinCitric Acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Citric Acid.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Citric Acid.Approved
CilostazolCilostazol may increase the anticoagulant activities of Citric Acid.Approved
ClonixinClonixin may increase the anticoagulant activities of Citric Acid.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical
CloricromenCloricromen may increase the anticoagulant activities of Citric Acid.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Citric Acid.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Citric Acid is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Citric Acid.Approved
CurcuminCurcumin may increase the anticoagulant activities of Citric Acid.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Citric Acid.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Citric Acid.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Citric Acid.Experimental
DalteparinCitric Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCitric Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanCitric Acid may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Citric Acid.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Citric Acid.Approved, Investigational
DemegestoneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Citric Acid.Investigational
DesirudinCitric Acid may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Citric Acid.Investigational
DesogestrelThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Desogestrel.Approved
DextranCitric Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Citric Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Citric Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Citric Acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Citric Acid.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Citric Acid.Approved, Investigational
DienogestThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Citric Acid.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Citric Acid.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Citric Acid.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Citric Acid.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Citric Acid.Approved
DitazoleDitazole may increase the anticoagulant activities of Citric Acid.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Citric Acid.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Citric Acid.Investigational
DydrogesteroneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Citric Acid.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Citric Acid.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Citric Acid.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Citric Acid.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Citric Acid.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Citric Acid.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Citric Acid.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Citric Acid.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Citric Acid.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Citric Acid.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Citric Acid.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Citric Acid.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Citric Acid.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Citric Acid.Approved
EstroneEstrone may decrease the anticoagulant activities of Citric Acid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Citric Acid.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Citric Acid.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Citric Acid.Approved
Ethyl biscoumacetateCitric Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Citric Acid.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Citric Acid.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Citric Acid.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Citric Acid.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Citric Acid.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Citric Acid.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Citric Acid.Approved
FentiazacFentiazac may increase the anticoagulant activities of Citric Acid.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Citric Acid.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Citric Acid.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Citric Acid.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Citric Acid.Approved, Withdrawn
FluindioneCitric Acid may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Citric Acid.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Citric Acid.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Citric Acid.Approved, Investigational
FondaparinuxCitric Acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Citric Acid.Approved, Investigational
GabexateCitric Acid may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Citric Acid.Investigational
GestodeneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Citric Acid.Experimental
HeminHemin may increase the anticoagulant activities of Citric Acid.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Citric Acid.Experimental
HeparinHeparin may increase the anticoagulant activities of Citric Acid.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Citric Acid.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Citric Acid.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Citric Acid.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Citric Acid is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Citric Acid.Approved
IbudilastIbudilast may increase the anticoagulant activities of Citric Acid.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Citric Acid.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Citric Acid.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Citric Acid.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical
IdraparinuxCitric Acid may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Citric Acid.Investigational
IloprostIloprost may increase the anticoagulant activities of Citric Acid.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Citric Acid.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Citric Acid.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Citric Acid.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Citric Acid.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Citric Acid.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Citric Acid.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Citric Acid.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Citric Acid.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Citric Acid.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Citric Acid.Approved
LetaxabanCitric Acid may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Citric Acid.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Citric Acid.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Citric Acid.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Citric Acid.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Citric Acid.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Citric Acid.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Citric Acid.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Citric Acid.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Citric Acid.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Citric Acid.Approved
Megestrol acetateThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranCitric Acid may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Citric Acid.Approved
MestranolMestranol may decrease the anticoagulant activities of Citric Acid.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Citric Acid.Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Citric Acid.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Citric Acid.Approved
MizoribineMizoribine may increase the anticoagulant activities of Citric Acid.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Citric Acid.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Citric Acid.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Citric Acid.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Citric Acid.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Citric Acid.Approved
NadroparinCitric Acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Citric Acid.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Citric Acid.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Citric Acid.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Citric Acid.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Citric Acid.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Citric Acid.Approved
NimesulideNimesulide may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Citric Acid is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Citric Acid.Investigational
NomegestrolThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Citric Acid is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Citric Acid.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Citric Acid.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Citric Acid is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical
OrgoteinOrgotein may increase the anticoagulant activities of Citric Acid.Vet Approved
OtamixabanCitric Acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Citric Acid.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Citric Acid.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Citric Acid.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Citric Acid.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Citric Acid.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Citric Acid.Investigational
Pentaerythritol TetranitrateCitric Acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Citric Acid.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Citric Acid.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Citric Acid.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Citric Acid.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Citric Acid.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Citric Acid.Approved
ProgesteroneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Citric Acid.Experimental
PromegestoneThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Citric Acid.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Citric Acid.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Citric Acid.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Citric Acid.Experimental
Protein CCitric Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanCitric Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCitric Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Citric Acid.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Citric Acid.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Citric Acid.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Citric Acid.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Citric Acid.Approved
ReviparinCitric Acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Citric Acid.Approved
RivaroxabanCitric Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Citric Acid.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Citric Acid.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Citric Acid.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Citric Acid.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Citric Acid.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Citric Acid.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Citric Acid.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Citric Acid.Approved
SemapimodSemapimod may increase the anticoagulant activities of Citric Acid.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Citric Acid.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Citric Acid.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Citric Acid.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Citric Acid.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Citric Acid.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Citric Acid.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Citric Acid.Approved
SulindacSulindac may increase the anticoagulant activities of Citric Acid.Approved
SulodexideCitric Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Citric Acid.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Citric Acid.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Citric Acid.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Citric Acid.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Citric Acid.Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Citric Acid.Approved
TenidapTenidap may increase the anticoagulant activities of Citric Acid.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Citric Acid.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Citric Acid.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Citric Acid.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Citric Acid.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Citric Acid.Approved
TiboloneTibolone may increase the anticoagulant activities of Citric Acid.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Citric Acid.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Citric Acid.Approved
TinoridineTinoridine may increase the anticoagulant activities of Citric Acid.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Citric Acid.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Citric Acid.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Citric Acid.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Citric Acid.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Citric Acid.Approved
TolmetinTolmetin may increase the anticoagulant activities of Citric Acid.Approved
TositumomabThe risk or severity of adverse effects can be increased when Citric Acid is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Citric Acid.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Citric Acid.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Citric Acid.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Citric Acid.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Citric Acid.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Citric Acid.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Citric Acid.Approved
TroxerutinCitric Acid may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Citric Acid.Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Citric Acid.Approved
WarfarinWarfarin may increase the anticoagulant activities of Citric Acid.Approved
XimelagatranCitric Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Citric Acid.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Citric Acid.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Citric Acid.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Citric Acid.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Karl E. Wiegand, "Chemical process for producing citric acid." U.S. Patent US3962287, issued 0000.

US3962287
General References
Not Available
External Links
Human Metabolome Database
HMDB00094
KEGG Drug
D00037
KEGG Compound
C00158
PubChem Compound
311
PubChem Substance
46508995
ChemSpider
305
BindingDB
14672
ChEBI
30769
ChEMBL
CHEMBL1261
PharmGKB
PA449021
IUPHAR
2478
Guide to Pharmacology
GtP Drug Page
HET
CIT
ATC Codes
A09AB04 — Citric acid
PDB Entries
1a59 / 1afl / 1agr / 1aj8 / 1az2 / 1b1e / 1b1i / 1cts / 1cwv / 1cxu
show 806 more
MSDS
Download (49.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentIron-refractory, Iron-deficiency Anemia (IRIDA)1
1WithdrawnTreatmentArthritis1
1, 2CompletedTreatmentNeed for Bowel Preparation1
2Active Not RecruitingTreatmentIron-Refractory Iron-Deficiency Anemia1
2CompletedScreeningHealthy Volunteers1
2, 3Unknown StatusTreatmentTreatment of Episodic Tension Headache1
3CompletedTreatmentBowel preparation therapy2
3RecruitingOtherBowel preparation therapy1
4CompletedNot AvailableBowel preparation therapy1
4CompletedDiagnosticColonoscopy1
4CompletedDiagnosticHemodynamics / Hyponatremias1
4CompletedTreatmentCathartic Colon1
4CompletedTreatmentColonoscopy1
4CompletedTreatmentPsoriasis / Sleep Apnea, Obstructive1
4Not Yet RecruitingDiagnosticBowel Preparation Solutions1
4Unknown StatusDiagnosticBowel preparation therapy / Colonoscopy1
4Unknown StatusTreatmentBowel Preparation Solutions / Endoscopy1
Not AvailableRecruitingNot AvailableIntra Operative Bleeding, Blood Salvage1
Not AvailableRecruitingDiagnosticBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous
SolutionIntravenous8 mg/mL
TabletOral
Aerosol, sprayTopical
Injection, solutionExtracorporeal
SolutionUnknown
Injection, solutionIntravenous
LiquidTopical1.5 g/30mL
Powder, for solutionOral
GranuleOral
SolutionHemodialysis
Granule, effervescentOral
SolutionIntravenous
Capsule, delayed release pelletsOral
SolutionExtracorporeal
LiquidTopical
LiquidTopical.3 g/100g
Tablet, effervescentOral
LiquidOral
PowderOral
Granule, for solutionOral
Powder, meteredOral
Powder, for solutionIrrigation; Topical
SolutionOral
SprayTopical.7 mg/100mL
SprayTopical7 mg/mL
SolutionIrrigation
LiquidIrrigation
LiquidTopical.007 g/mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8450338No2008-10-102028-10-10Us
US8481083No2008-10-102028-10-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)153 °CPhysProp
water solubility5.92E+005 mg/L (at 20 °C)MERCK INDEX (1989)
logP-1.64AVDEEF,A (1997)
logS0.51ADME Research, USCD
pKa2.79SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility106.0 mg/mLALOGPS
logP-1.3ALOGPS
logP-1.3ChemAxon
logS-0.26ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area132.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity35.62 m3·mol-1ChemAxon
Polarizability15.54 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7518
Blood Brain Barrier+0.855
Caco-2 permeable-0.8634
P-glycoprotein substrateNon-substrate0.6125
P-glycoprotein inhibitor INon-inhibitor0.9694
P-glycoprotein inhibitor IINon-inhibitor0.9658
Renal organic cation transporterNon-inhibitor0.9624
CYP450 2C9 substrateNon-substrate0.8641
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateNon-substrate0.6809
CYP450 1A2 substrateNon-inhibitor0.9336
CYP450 2C9 inhibitorNon-inhibitor0.9399
CYP450 2D6 inhibitorNon-inhibitor0.9476
CYP450 2C19 inhibitorNon-inhibitor0.9396
CYP450 3A4 inhibitorNon-inhibitor0.8735
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9904
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8206
BiodegradationReady biodegradable0.6288
Rat acute toxicity1.7748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9948
hERG inhibition (predictor II)Non-inhibitor0.9577
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)GC-MSsplash10-0002-0941000000-c310fda0e6a19bf6ae40
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)GC-MSsplash10-0002-0941000000-f1dfda3e9abc7cfb6b2a
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)GC-MSsplash10-006t-0952000000-ba3a1a80815f65afd05c
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0002-0951000000-48857e9baebe16d9fc8d
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)GC-MSsplash10-00di-9531000000-b6fd7d038634694f0873
GC-MS Spectrum - GC-MS (4 TMS)GC-MSsplash10-00di-0593000000-b193bbba8c0cefdfe42a
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0941000000-c310fda0e6a19bf6ae40
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0941000000-f1dfda3e9abc7cfb6b2a
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-006t-0952000000-ba3a1a80815f65afd05c
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0951000000-48857e9baebe16d9fc8d
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9531000000-b6fd7d038634694f0873
GC-MS Spectrum - GC-MSGC-MSsplash10-00di-0593000000-b193bbba8c0cefdfe42a
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0941000000-573230e47a4efb1e36a5
Mass Spectrum (Electron Ionization)MSsplash10-002f-9400000000-fb757b614278bb898b54
MS/MS Spectrum - Quattro_QQQ 10V, NegativeLC-MS/MSsplash10-03di-2900000000-956001b034bbc0b7da96
MS/MS Spectrum - Quattro_QQQ 25V, NegativeLC-MS/MSsplash10-000l-9100000000-55e34e2c1616942fd4f2
MS/MS Spectrum - Quattro_QQQ 40V, NegativeLC-MS/MSsplash10-000f-9000000000-7b8be3e90a4daf85f04a
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0006-0911200000-af80d22f720facc4813a
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-014i-9000000000-6f4fedbb19821898fb22
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03di-0900000000-8eff68ab89f7ce2262be
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0fsi-0019300000-b370c4c3dd656c8eb729
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0006-0912100000-05e8ceb6dd97f7b9af98
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-014i-9000000000-e4b67745443c48a63bd6
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03di-0900000000-92536abec982e0a653a0
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03di-0190000000-35772df08490f451d828
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-0006-0900000000-35856cc258368d13e1ff
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-03di-3900000000-7170fdcb9749e6d6c2fb
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-01p9-9500000000-9a502981b0a9e1ea35ad
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-000i-9100000000-ed0c86b90e1f4966d025
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0a4r-9000000000-b8a975c2d639d8c91afb
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-03di-2900000000-30970a4250098e148658
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-0900000000-a587dddf188152c5d7b0
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-3900000000-7170fdcb9749e6d6c2fb
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-01p9-9500000000-9a502981b0a9e1ea35ad
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-9100000000-42a125e9128ce21bd785
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4r-9000000000-b8a975c2d639d8c91afb
LC-MS/MS Spectrum - LC-ESI-IT , negativeLC-MS/MSsplash10-03di-0900000000-32af4c1bf55ea1563e53
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-9000000000-6f4fedbb19821898fb22
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-8eff68ab89f7ce2262be
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-9000000000-e4b67745443c48a63bd6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-009ac4e65a37a8aa2b24
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03di-2900000000-30970a4250098e148658
MS/MS Spectrum - , negativeLC-MS/MSsplash10-03dr-5900000000-1dc82963a3a52c19886b
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Alpha hydroxy acids and derivatives / Tertiary alcohols / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Tricarboxylic acid or derivatives / Hydroxy acid / Alpha-hydroxy acid / Tertiary alcohol / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
tricarboxylic acid (CHEBI:30769)

Targets

Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
Essential cell division protein that forms a contractile ring structure (Z ring) at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. One of the functions of the FtsZ ring is to recruit other cell division proteins to the septum to produce a new cell wall between the dividing cells. Binds GTP and shows GTPase activity.
Specific Function
Gtp binding
Gene Name
ftsZ
Uniprot ID
P9WN95
Uniprot Name
Cell division protein FtsZ
Molecular Weight
38755.52 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Rrna binding
Specific Function
Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. Stimulates ribosomal RNA synthesis including that containing the initiatio...
Gene Name
ANG
Uniprot ID
P03950
Uniprot Name
Angiogenin
Molecular Weight
16549.95 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Bacillus cereus
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Can hydrolyze carbapenem compounds.
Gene Name
blm
Uniprot ID
P04190
Uniprot Name
Beta-lactamase 2
Molecular Weight
28092.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Uridine kinase activity
Specific Function
Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate. Does not phosphorylate deoxyribonucleosides or purine ribonucleosides. Can use ATP or GTP as a phosphate don...
Gene Name
UCK2
Uniprot ID
Q9BZX2
Uniprot Name
Uridine-cytidine kinase 2
Molecular Weight
29298.92 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-ce...
Gene Name
TNFSF13B
Uniprot ID
Q9Y275
Uniprot Name
Tumor necrosis factor ligand superfamily member 13B
Molecular Weight
31222.48 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Involved in the regulation of homocysteine metabolism. Converts betaine and homocysteine to dimethylglycine and methionine, respectively. This reaction is also required for the irreversible oxidati...
Gene Name
BHMT
Uniprot ID
Q93088
Uniprot Name
Betaine--homocysteine S-methyltransferase 1
Molecular Weight
44998.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
Unknown
General Function
Tryptophan-trna ligase activity
Specific Function
Not Available
Gene Name
trpS
Uniprot ID
P00953
Uniprot Name
Tryptophan--tRNA ligase
Molecular Weight
37192.385 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Glyceraldehyde oxidoreductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
Gene Name
AKR1B1
Uniprot ID
P15121
Uniprot Name
Aldose reductase
Molecular Weight
35853.125 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Not Available
Gene Name
CS
Uniprot ID
O75390
Uniprot Name
Citrate synthase, mitochondrial
Molecular Weight
51712.025 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sulfotransferase activity
Specific Function
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to an N-unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan ...
Gene Name
HS3ST3A1
Uniprot ID
Q9Y663
Uniprot Name
Heparan sulfate glucosamine 3-O-sulfotransferase 3A1
Molecular Weight
44899.155 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, ...
Gene Name
PDE5A
Uniprot ID
O76074
Uniprot Name
cGMP-specific 3',5'-cyclic phosphodiesterase
Molecular Weight
99984.14 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sh3/sh2 adaptor activity
Specific Function
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion recept...
Gene Name
SRC
Uniprot ID
P12931
Uniprot Name
Proto-oncogene tyrosine-protein kinase Src
Molecular Weight
59834.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ribonuclease a activity
Specific Function
Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single-stranded and double-stranded RNA.
Gene Name
RNASE1
Uniprot ID
P07998
Uniprot Name
Ribonuclease pancreatic
Molecular Weight
17644.125 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
Unknown
General Function
Nad binding
Specific Function
Not Available
Gene Name
icd
Uniprot ID
P39126
Uniprot Name
Isocitrate dehydrogenase [NADP]
Molecular Weight
46417.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Glycine n-methyltransferase activity
Specific Function
Catalyzes the methylation of glycine by using S-adenosylmethionine (AdoMet) to form N-methylglycine (sarcosine) with the concomitant production of S-adenosylhomocysteine (AdoHcy). Possible crucial ...
Gene Name
GNMT
Uniprot ID
Q14749
Uniprot Name
Glycine N-methyltransferase
Molecular Weight
32742.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ribonuclease activity
Specific Function
Cytotoxin and helminthotoxin with low-efficiency ribonuclease activity. Possesses a wide variety of biological activities. Exhibits antibacterial activity, including cytoplasmic membrane depolariza...
Gene Name
RNASE3
Uniprot ID
P12724
Uniprot Name
Eosinophil cationic protein
Molecular Weight
18385.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Details
17. Beta-lactamase
Kind
Protein
Organism
Bacillus licheniformis
Pharmacological action
Unknown
General Function
Beta-lactamase activity
Specific Function
Not Available
Gene Name
penP
Uniprot ID
P00808
Uniprot Name
Beta-lactamase
Molecular Weight
33995.36 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Molybdenum cofactor guanylyltransferase activity
Specific Function
Transfers a GMP moiety from GTP to Mo-molybdopterin (Mo-MPT) cofactor (Moco or molybdenum cofactor) to form Mo-molybdopterin guanine dinucleotide (Mo-MGD) cofactor. Is also involved in the biosynth...
Gene Name
mobA
Uniprot ID
P32173
Uniprot Name
Molybdenum cofactor guanylyltransferase
Molecular Weight
21642.735 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Fumarate hydratase activity
Specific Function
Catalyzes the reversible addition of water to fumarate to give L-malate.
Gene Name
fumC
Uniprot ID
P05042
Uniprot Name
Fumarate hydratase class II
Molecular Weight
50488.44 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
6-phosphogluconolactonase activity
Specific Function
Hydrolysis of 6-phosphogluconolactone to 6-phosphogluconate.
Gene Name
pgl
Uniprot ID
Q9X0N8
Uniprot Name
6-phosphogluconolactonase
Molecular Weight
25324.955 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Nad(p)h nitroreductase activity
Specific Function
Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred. Capable of reducing nitrofurazone, quinon...
Gene Name
nfsB
Uniprot ID
P38489
Uniprot Name
Oxygen-insensitive NAD(P)H nitroreductase
Molecular Weight
23904.99 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
RSV-SRA
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Capsid protein p27 forms the spherical core of the virus that encapsulates the genomic RNA-nucleocapsid complex.The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins ...
Gene Name
gag-pro-pol
Uniprot ID
Q04095
Uniprot Name
Gag-Pro-Pol polyprotein
Molecular Weight
173931.55 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
L-amino-acid oxidase activity
Specific Function
Lysosomal L-amino-acid oxidase with highest specific activity with phenylalanine. May play a role in lysosomal antigen processing and presentation (By similarity).
Gene Name
IL4I1
Uniprot ID
Q96RQ9
Uniprot Name
L-amino-acid oxidase
Molecular Weight
62880.52 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of ma...
Gene Name
MIF
Uniprot ID
P14174
Uniprot Name
Macrophage migration inhibitory factor
Molecular Weight
12476.19 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RN...
Gene Name
CTDSP1
Uniprot ID
Q9GZU7
Uniprot Name
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1
Molecular Weight
29202.94 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Nadph binding
Specific Function
Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP).
Gene Name
dxr
Uniprot ID
P45568
Uniprot Name
1-deoxy-D-xylulose 5-phosphate reductoisomerase
Molecular Weight
43387.575 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Thermus thermophilus (strain HB27 / ATCC BAA-163 / DSM 7039)
Pharmacological action
Unknown
General Function
Tryptophan synthase activity
Specific Function
The alpha subunit is responsible for the aldol cleavage of indoleglycerol phosphate to indole and glyceraldehyde 3-phosphate.
Gene Name
trpA
Uniprot ID
P16608
Uniprot Name
Tryptophan synthase alpha chain
Molecular Weight
28936.25 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Micromonospora viridifaciens
Pharmacological action
Unknown
General Function
Exo-alpha-(2->8)-sialidase activity
Specific Function
To release sialic acids for use as carbon and energy sources for this non-pathogenic bacterium while in pathogenic microorganisms, sialidases have been suggested to be pathogenic factors.
Gene Name
nedA
Uniprot ID
Q02834
Uniprot Name
Sialidase
Molecular Weight
68829.78 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Involved in the degradation of glucose via the Entner-Doudoroff pathway. Catalyzes the reversible, stereospecific retro-aldol cleavage of 2-Keto-3-deoxy-6-phosphogluconate (KDPG) to pyruvate and D-...
Gene Name
eda
Uniprot ID
P0A955
Uniprot Name
KHG/KDPG aldolase
Molecular Weight
22283.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Marinobacter hydrocarbonoclasticus
Pharmacological action
Unknown
General Function
Oxidoreductase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
P83787
Uniprot Name
Cytochrome c peroxidase
Molecular Weight
35354.415 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein domain specific binding
Specific Function
Involved in intracellular signal transduction mediated by cytokines and growth factors. When associated with STAM, it suppresses DNA signaling upon stimulation by IL-2 and GM-CSF. Could be a direct...
Gene Name
HGS
Uniprot ID
O14964
Uniprot Name
Hepatocyte growth factor-regulated tyrosine kinase substrate
Molecular Weight
86191.46 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Yersinia pseudotuberculosis serotype I (strain IP32953)
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Invasin is a protein that allows enteric bacteria to penetrate cultured mammalian cells. The entry of invasin in the cell is mediated by binding several beta-1 chain integrins.
Gene Name
Not Available
Uniprot ID
P11922
Uniprot Name
Invasin
Molecular Weight
106543.46 Da
Kind
Protein
Organism
Enterobacteria phage T4
Pharmacological action
Unknown
General Function
Endonuclease activity
Specific Function
This endonuclease is specific to the thymidylate synthase (td) gene splice junction and is involved in intron homing.
Gene Name
ITEVIR
Uniprot ID
P13299
Uniprot Name
Intron-associated endonuclease 1
Molecular Weight
28232.2 Da
Kind
Protein
Organism
Enterobacteria phage T4
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Structural component of the short tail fiber. Adhesion protein that binds irreversibly to the lipopolysaccharides component (LPS) on the cell surface of Escherichia coli B strains during virus atta...
Gene Name
12
Uniprot ID
P10930
Uniprot Name
Short tail fiber protein gp12
Molecular Weight
56204.88 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Not Available
Gene Name
MDH2
Uniprot ID
P40926
Uniprot Name
Malate dehydrogenase, mitochondrial
Molecular Weight
35502.935 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Acetobacter aceti
Pharmacological action
Unknown
General Function
5-(carboxyamino)imidazole ribonucleotide mutase activity
Specific Function
Catalyzes the conversion of N5-carboxyaminoimidazole ribonucleotide (N5-CAIR) to 4-carboxy-5-aminoimidazole ribonucleotide (CAIR).
Gene Name
purE
Uniprot ID
Q2QJL3
Uniprot Name
N5-carboxyaminoimidazole ribonucleotide mutase
Molecular Weight
18734.295 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with diff...
Gene Name
rplD
Uniprot ID
P38516
Uniprot Name
50S ribosomal protein L4
Molecular Weight
26630.77 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
CPB1
Uniprot ID
P15086
Uniprot Name
Carboxypeptidase B
Molecular Weight
47367.11 Da
Kind
Protein
Organism
HAdV-2
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Major capsid protein that self-associates to form 240 hexon trimers, each in the shape of a hexagon, building most of the pseudo T=25 capsid. Assembled into trimeric units with the help of the chap...
Gene Name
Not Available
Uniprot ID
P03277
Uniprot Name
Hexon protein
Molecular Weight
109151.995 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Riboflavin kinase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q9WZW1
Uniprot Name
Riboflavin biosynthesis protein
Molecular Weight
33613.56 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Sucrose alpha-glucosidase activity
Specific Function
Hydrolysis of sucrose, raffinose, inulin and levan. Specific for the fructose moiety and the beta-anomeric configuration of the glycosidic linkages of its substrates. The enzyme released fructose f...
Gene Name
bfrA
Uniprot ID
O33833
Uniprot Name
Beta-fructosidase
Molecular Weight
49841.065 Da
Kind
Protein
Organism
Yersinia pestis
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
sspA
Uniprot ID
Q7CL96
Uniprot Name
Putative stringent starvation protein A
Molecular Weight
24524.98 Da
Kind
Protein
Organism
Thermus thermophilus
Pharmacological action
Unknown
General Function
Transferase activity, transferring acyl groups, acyl groups converted into alkyl on transfer
Specific Function
Not Available
Gene Name
cit
Uniprot ID
Q9LCX9
Uniprot Name
Citrate synthase
Molecular Weight
42322.13 Da
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Rna-3'-phosphate cyclase activity
Specific Function
Catalyzes the conversion of 3'-phosphate to a 2',3'-cyclic phosphodiester at the end of RNA. The mechanism of action of the enzyme occurs in 3 steps: (A) adenylation of the enzyme by ATP; (B) trans...
Gene Name
rtcA
Uniprot ID
P46849
Uniprot Name
RNA 3'-terminal phosphate cyclase
Molecular Weight
35902.925 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Component of LSm protein complexes, which are involved in RNA processing and may function in a chaperone-like manner, facilitating the efficient association of RNA processing factors with their sub...
Gene Name
LSM6
Uniprot ID
P62312
Uniprot Name
U6 snRNA-associated Sm-like protein LSm6
Molecular Weight
9127.525 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol-3,4-bisphosphate binding
Specific Function
Binds specifically to phosphatidylinositol 3,4-diphosphate (PtdIns3,4P2), but not to other phosphoinositides. May recruit other proteins to the plasma membrane.
Gene Name
PLEKHA1
Uniprot ID
Q9HB21
Uniprot Name
Pleckstrin homology domain-containing family A member 1
Molecular Weight
45553.165 Da
Kind
Protein
Organism
Serratia marcescens
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
Part of the ABC transporter complex FbpABC (TC 3.A.1.10.1) involved in Fe(3+) ions import. This protein specifically binds Fe(3+) and is involved in its transmembrane transport (By similarity).
Gene Name
fbpA
Uniprot ID
P21408
Uniprot Name
Fe(3+)-binding periplasmic protein
Molecular Weight
36157.015 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Gtpase activity
Specific Function
Involved in targeting and insertion of nascent membrane proteins into the cytoplasmic membrane. Acts as a receptor for the complex formed by the signal recognition particle (SRP) and the ribosome-n...
Gene Name
ftsY
Uniprot ID
Q9WZ40
Uniprot Name
Signal recognition particle receptor FtsY
Molecular Weight
32045.975 Da
Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Unknown
General Function
Nicotinate-nucleotide adenylyltransferase activity
Specific Function
Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD).
Gene Name
nadD
Uniprot ID
P0A753
Uniprot Name
Nicotinate-nucleotide adenylyltransferase
Molecular Weight
24527.75 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Rna binding
Specific Function
Involved in the transcription termination process.
Gene Name
nusB
Uniprot ID
Q9X286
Uniprot Name
N utilization substance protein B homolog
Molecular Weight
16973.325 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Retinol binding
Specific Function
C8 is a constituent of the membrane attack complex. C8 binds to the C5B-7 complex, forming the C5B-8 complex. C5-B8 binds C9 and acts as a catalyst in the polymerization of C9. The gamma subunit se...
Gene Name
C8G
Uniprot ID
P07360
Uniprot Name
Complement component C8 gamma chain
Molecular Weight
22277.285 Da
Kind
Protein
Organism
Mycobacterium leprae (strain TN)
Pharmacological action
Unknown
General Function
Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor
Specific Function
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides (By similarity).
Gene Name
nrdF
Uniprot ID
Q9CBQ2
Uniprot Name
Ribonucleoside-diphosphate reductase subunit beta
Molecular Weight
37315.67 Da
Kind
Protein group
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
Involved in nitrogen metabolism via ammonium assimilation. Catalyzes the ATP-dependent biosynthesis of glutamine from glutamate and ammonia (PubMed:7937767, PubMed:12819079). Also able to use GTP (PubMed:7937767). D-glutamate is a poor substrate, and DL-glutamate shows about 50% of the standard specific activity (PubMed:7937767). Also plays a key role in controlling the ammonia levels within infected host cells and so contributes to the pathogens capacity to inhibit phagosome acidification and phagosome-lysosome fusion (PubMed:7937767, PubMed:12819079). Involved in cell wall biosynthesis via the production of the major component poly-L-glutamine (PLG) (PubMed:7937767, PubMed:10618433). PLG synthesis in the cell wall occurs only in nitrogen limiting conditions and on the contrary high nitrogen conditions inhibit PLG synthesis (Probable).
Specific Function
Atp binding

Components:
Kind
Protein
Organism
Antarctic bacterium DS2-3R
Pharmacological action
Unknown
General Function
Citrate synthase activity
Specific Function
Involved in the catabolism of short chain fatty acids (SCFA) via the tricarboxylic acid (TCA)(acetyl degradation route) and via the 2-methylcitrate cycle I (propionate degradation route). Catalyzes...
Gene Name
gltA
Uniprot ID
O34002
Uniprot Name
2-methylcitrate synthase
Molecular Weight
41832.0 Da
Kind
Protein
Organism
Trypanosoma brucei brucei
Pharmacological action
Unknown
General Function
Prostaglandin-f synthase activity
Specific Function
Catalyzes the NADP-dependent formation of prostaglandin F2-alpha from prostaglandin H2. Has also aldo/ketoreductase activity towards the synthetic substrates 9,10-phenanthrenequinone and p-nitroben...
Gene Name
Not Available
Uniprot ID
Q9GV41
Uniprot Name
Prostaglandin F synthase
Molecular Weight
30992.385 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Amp binding
Specific Function
Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis.
Gene Name
APRT
Uniprot ID
P07741
Uniprot Name
Adenine phosphoribosyltransferase
Molecular Weight
19607.535 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
Pharmacological action
Unknown
General Function
Nucleotide binding
Specific Function
Catalyzes the formation of dTDP-glucose, from dTTP and glucose 1-phosphate, as well as its pyrophosphorolysis.
Gene Name
rmlA
Uniprot ID
Q9HU22
Uniprot Name
Glucose-1-phosphate thymidylyltransferase
Molecular Weight
32456.65 Da
Kind
Protein
Organism
Bacillus cereus (strain ATCC 14579 / DSM 31)
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q81F54
Uniprot Name
Glyoxalase family protein
Molecular Weight
16581.885 Da
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Copper ion binding
Specific Function
Not Available
Gene Name
yfiH
Uniprot ID
P33644
Uniprot Name
Laccase domain protein YfiH
Molecular Weight
26338.69 Da
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Unknown
General Function
Ribose-5-phosphate isomerase activity
Specific Function
Catalyzes the reversible conversion of ribose-5-phosphate to ribulose 5-phosphate.
Gene Name
rpiA
Uniprot ID
P44725
Uniprot Name
Ribose-5-phosphate isomerase A
Molecular Weight
23093.47 Da
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Pyrophosphatase activity
Specific Function
Catalyzes the synthesis of GMP from XMP.
Gene Name
guaA
Uniprot ID
P04079
Uniprot Name
GMP synthase [glutamine-hydrolyzing]
Molecular Weight
58678.78 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xtp diphosphatase activity
Specific Function
Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) an...
Gene Name
ITPA
Uniprot ID
Q9BY32
Uniprot Name
Inosine triphosphate pyrophosphatase
Molecular Weight
21445.495 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Enterobacteria phage P1
Pharmacological action
Unknown
General Function
Lysozyme activity
Specific Function
Essential for lysis of bacterial cell wall, by showing cell wall hydrolyzing activity.
Gene Name
17
Uniprot ID
Q37875
Uniprot Name
Lysozyme
Molecular Weight
20256.17 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q9X1F0
Uniprot Name
Glycerol uptake operon antiterminator regulatory protein
Molecular Weight
19296.645 Da
Kind
Protein
Organism
Pseudomonas putida
Pharmacological action
Unknown
General Function
3-carboxy-cis,cis-muconate cycloisomerase activity
Specific Function
Catalyzes an anti cycloisomerization.
Gene Name
pcaB
Uniprot ID
P32427
Uniprot Name
3-carboxy-cis,cis-muconate cycloisomerase
Molecular Weight
44675.755 Da
Kind
Protein
Organism
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Pharmacological action
Unknown
General Function
Thiamine pyrophosphate binding
Specific Function
Not Available
Gene Name
pdc
Uniprot ID
P06672
Uniprot Name
Pyruvate decarboxylase
Molecular Weight
60925.005 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 17:24